Bayesian Capital Management’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$85.3K Buy
+19,800
New +$83.5K 0.07% 164
2025
Q4
– Sell
-15,400
Closed -$111K – 390
2025
Q3
$111K Buy
+15,400
New +$91.4K 0.02% 482
2024
Q3
– Sell
-19,400
Closed -$475K – 927
2024
Q2
$475K Buy
+19,400
New +$426K 0.05% 387
2018
Q1
– Sell
-22,800
Closed -$783K – 743
2017
Q4
$783K Buy
+22,800
New +$769K 0.16% 217
2017
Q3
– Sell
-23,000
Closed -$594K – 592
2017
Q2
$594K Sell
23,000
-7,100
-24% -$151K 0.22% 155
2017
Q1
$578K Buy
+30,100
New +$533K 0.27% 130

Other funds holding MYGN

Bayesian Capital Management's MYGN Position: Q3 2026 in Review

Bayesian Capital Management opened a new position in Myriad Genetics (MYGN) in Q3 2026: 19,800 shares worth $85.3K. The stake represents 0.07% of the portfolio and ranks #164 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in MYGN as recently as Q3 2025.

Bayesian Capital Management first reported a position in MYGN in Q1 2017 and has held it in 6 quarters since. The position peaked at $783K in Q4 2017. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

  • Bayesian Capital Management held 19,800 shares of Myriad Genetics worth $85.3K as of Q3 2026.
  • Myriad Genetics was a new Bayesian Capital Management position in Q3 2026.
  • Myriad Genetics made up 0.07% of Bayesian Capital Management's portfolio in Q3 2026, its #164 holding.
  • Bayesian Capital Management first reported a position in Myriad Genetics in Q1 2017 and has held it in 6 quarters since.
  • Bayesian Capital Management's Myriad Genetics position peaked at $783K in Q4 2017.
  • 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on Bayesian Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.